Generate Biomedicines Faces Rocky Nasdaq Debut as Shares Dip
Generate Biomedicines Faces Rocky Nasdaq Debut as Shares Dip is drawing significant interest across the industry.
Generate Biomedicines, a Massachusetts-based drug developer backed by Flagship, saw its shares plunge over 6% during its Nasdaq debut. The company's IPO, priced at $16, managed to raise $400 million by selling 25 million shares. Market volatility continued to concern investors regarding new listings.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- NCAA's Charlie Baker reiterates support for expanded tournament
- University drop outs owe £12bn in student loans after being 'pushed' into degrees
- ONGC Receives Equity Shares from Joint Venture Companies in Gift City
- Microsoft's new 10,000-year data storage medium: glass
Source: Original →